Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL (2022) Cancer statistics for African American/black people 2022. CA Cancer J Clin 72:202–229. https://doi.org/10.3322/caac.21718

Article  PubMed  Google Scholar 

Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS et al (2021) Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open 4:e2119568. https://doi.org/10.1001/jamanetworkopen.2021.19568

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ et al (2018) Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 68:31–54. https://doi.org/10.3322/caac.21440

Article  PubMed  Google Scholar 

Pagadala MS, Lui A, Lynch J, Karunamuni R, Lee KM, Plym A et al (2022) Healthy lifestyle and prostate cancer risk in the Million Veteran. Program. https://doi.org/10.1101/2022.07.09.22277437

Article  Google Scholar 

Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J et al (2020) Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol 77:24–35. https://doi.org/10.1016/j.eururo.2019.08.025

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH et al (2018) Role of genetic testing for inherited prostate cancer risk: philadelphia prostate cancer consensus conference 2017. J Clin Oncol 36:414–424. https://doi.org/10.1200/JCO.2017.74.1173

Article  CAS  PubMed  Google Scholar 

Ferlay J, Ervik M, Lam F, Laversanne, M Colombet M, Mery L, Piñeros M et al. (2024) Global cancer observatory: cancer today. Int Agency Res Cancer. https://gco.iarc.who.int/today. Accessed 18 Jan 2025

Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S (2021) BRCA mutations in prostate cancer: assessment, implications and treatment considerations. Int J Mol Sci 22:12628. https://doi.org/10.3390/ijms222312628

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andreas ML, Ali A-T, Jan M, Claudia H-M, Dagmar SL, Martina K et al (2019) Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. Cancer Biol Med 16:319. https://doi.org/10.20892/j.issn.2095-3941.2018.0384

Article  CAS  Google Scholar 

Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM (2019) Bringing prostate cancer germline genetics into clinical practice. J Urol 202:223–230. https://doi.org/10.1097/JU.0000000000000137

Article  PubMed  Google Scholar 

Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63–89. https://doi.org/10.14740/wjon1191

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhanji Y, Isaacs WB, Xu J, Cooney KA (2021) Prostate cancer predisposition. Urol Clin North Am 48:283–296. https://doi.org/10.1016/j.ucl.2021.03.001

Article  PubMed  Google Scholar 

Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW et al (2018) Screening for prostate cancer. JAMA 319:1901. https://doi.org/10.1001/jama.2018.3710

Article  PubMed  Google Scholar 

Gupta S, Gupta A, Saini AK, Majumder K, Sinha K, Chahal A (2017) Prostate cancer: How young is too young? Curr Urol 9:212–215. https://doi.org/10.1159/000447143

Article  PubMed  Google Scholar 

Gerard S, Mourey L, Briand M, Delaunay B, Balardy L (2022) Prostate diseases. In: Sinclair AJ, Morley JE, Vellas B, Cesari M, Munshi M (eds) Pathy’s principles and practice of geriatric medicine. Wiley, Hoboken. https://doi.org/10.1002/9781119484288

Chapter  Google Scholar 

Akinnuwesi BA, Olayanju KA, Aribisala BS, Fashoto SG, Mbunge E, Okpeku M et al (2023) Application of support vector machine algorithm for early differential diagnosis of prostate cancer. Data Sci Manag 6:1–12. https://doi.org/10.1016/j.dsm.2022.10.001

Article  Google Scholar 

Lodhia J (2024) Case report advanced mucinous colorectal carcinoma in a teenager : a case report of a changing age paradigm 29:9–15. https://doi.org/10.4314/ecajs.v29i3.3

Gkotzamanidou M, Lazaris AC, Spapis V, Spetsieris N, Tsagaraki P (2018) Prostate gland pathology. In: Lazaris AC (ed) Clinical genitourinary pathology: a case-based learning approach. Springer International Publishing, Cham, pp 267–395. https://doi.org/10.1007/978-3-319-72194-1_3

Chapter  Google Scholar 

Grignon DJ (2018) Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens. Mod Pathol 31:96–109. https://doi.org/10.1038/modpathol.2017.167

Article  Google Scholar 

Shieh AC, Guler E, Ojili V, Paspulati RM, Elliott R, Ramaiya NH et al (2020) Extraprostatic extension in prostate cancer: primer for radiologists. Abdom Radiol 45:4040–4051. https://doi.org/10.1007/s00261-020-02555-x

Article  Google Scholar 

Agosti V, Munari E (2024) Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects. Asian J Androl 26:575–581. https://doi.org/10.4103/aja202440

Article  PubMed  PubMed Central  Google Scholar 

Duffy MJ (2020) Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med 58:326–339. https://doi.org/10.1515/cclm-2019-0693

Article  CAS  PubMed  Google Scholar 

Garrido MM, Bernardino RM, Marta JC, Holdenrieder S, Guimarães JT (2022) Tumour markers in prostate cancer: the post-prostate-specific antigen era. Ann Clin Biochem Int J Lab Med 59:46–58. https://doi.org/10.1177/00045632211041890

Article  CAS  Google Scholar 

Warli SM, Warli MH, Prapiska FF (2023) PCA3 and TMPRSS2: ERG urine level as diagnostic biomarker of prostate cancer. Res Rep Urol 15:149–155. https://doi.org/10.2147/RRU.S401131

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raja N, Russell CM, George AK (2018) Urinary markers aiding in the detection and risk stratification of prostate cancer. Transl Androl Urol 7:S436–S442. https://doi.org/10.21037/tau.2018.07.01

Article  PubMed  PubMed Central  Google Scholar 

Wasim S, Lee S-Y, Kim J (2022) Complexities of prostate cancer. Int J Mol Sci 23:14257. https://doi.org/10.3390/ijms232214257

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gandhi J, Afridi A, Vatsia S, Joshi G, Joshi G, Kaplan SA et al (2018) The molecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer Prostatic Dis 21:22–36. https://doi.org/10.1038/s41391-017-0023-8

Article  CAS  PubMed  Google Scholar 

Xia H, Zhan Y, Wang L, Wang X (2024) Exploring the interplay between circadian rhythms and prostate cancer: insights into androgen receptor signaling and therapeutic opportunities. Front Cell Dev Biol. https://doi.org/10.3389/fcell.2024.1421204

Article  PubMed  PubMed Central  Google Scholar 

Tsang ML (2021) Chemotherapy and prostate cancer. In: Trabulsi EJ, Lallas CD, Lizardi-Calvaresi AE (eds) Chemotherapy and immunotherapy in urologic oncology: a guide for the advanced practice provider. Springer International Publishing, Cham, pp 105–108. https://doi.org/10.1007/978-3-030-52021-2_9

Chapter  Google Scholar 

Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M et al (2022) Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: The CABADOC trial. Eur Urol 81:234–240. https://doi.org/10.1016/j.eururo.2021.10.016

Article  CAS  PubMed  Google Scholar 

Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM (2019) Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer. Urol Oncol Semin Orig Investig 37:688–695. https://doi.org/10.1016/j.urolonc.2019.05.017

Article